Expression of the adipocytokine resistin and its association with the clinicopathological features and prognosis of pancreatic ductal adenocarcinoma
Expression of the adipocytokine resistin and its association with the clinicopathological features and prognosis of pancreatic ductal adenocarcinoma
复制标题
脂肪细胞因子抵抗素的表达及其与胰腺导管腺癌临床病理特征和预后的关系
DOI：
10.3892/ol.2012.865
复制
发表时间：
2012-11-01
期刊：
影响因子：
2.9
通讯作者：
Wang, Liu-Bo
中科院分区：
文献类型：
--
作者：
Jiang, Chong-Yi;Wang, Wei;Wang, Liu-Bo
脂肪组织被认为是一个活跃的内分泌器官，可分泌多种生物活性物质。抵抗素是一种脂肪细胞分泌的因子，被认为与肥胖、胰岛素抵抗和炎症密切相关，这是胰腺癌进展的三个最重要的危险因素。然而，胰腺癌和胰腺癌之间的关系仍然是未知的。在这项研究中，45例胰腺导管腺癌患者的胰腺肿瘤标本进行了分析与免疫组化的表达。分析其与临床病理特征及预后的关系。48.9%（22/45）的病例观察到抵抗素染色。抵抗素在低分化肿瘤中的表达（9/9，100%）高于中分化肿瘤（11/28，39.3%）和高分化肿瘤（28，25%）（p <0.01）。日本胰腺学会III-IV期患者中的Ign表达发生率（18/27，66.7%）显著高于I-II期受试者（4/18，22.2%）（p <0.01）。耐药蛋白染色肿瘤患者的无复发生存时间（中位数，9个月）显著短于阴性肿瘤患者（中位数，18个月）（p <0.05）。此外，多因素分析显示，cDNAn表达是胰腺导管腺癌患者无复发生存期的独立预后因素（p <0.05）。这些结果表明，cDNAn可能会影响胰腺肿瘤的进展，并可能是一个有用的预测胰腺导管腺癌患者的无复发生存。
Fat tissue is viewed as an active endocrine organ that secretes a variety of bioactive substances. Resistin, an adipocyte-secreted factor, is thought to be closely related to obesity, insulin resistance and inflammation, the three most significant risk factors for the progression of pancreatic cancer. However, the association between resistin and pancreatic cancer is still unknown. In this study, pancreatic tumor samples from 45 patients with pancreatic ductal adenocarcinoma were analyzed with immunohistochemistry for the expression of resistin. The correlation between resistin expression and clinicopathological features and prognosis were evaluated. Resistin staining was observed in 48.9% (22 of 45) of the cases. Resistin expression was more frequent in poorly differentiated tumors (9 of 9, 100%) compared to moderately differentiated tumors (11 of 28, 39.3%) and well-differentiated tumors (2 of 8, 25%) (p<0.01). The incidence of resistin expression in patients with Japan Pancreas Society stages III-IV (18 of 27, 66.7%) was significantly higher than in subjects with stages I-II (4 of 18, 22.2%) (p<0.01). Patients with resistin-stained tumors had significantly shorter relapse-free survival times (median, 9 months) than patients with negative tumors (median, 18 months) (p<0.05). In addition, multivariate analysis showed that resistin expression was an independent prognostic factor for relapse-free survival of patients with pancreatic ductal adenocarcinoma (p<0.05). These results demonstrate that resistin may influence the progression of pancreatic tumors and may be a useful predictor of relapse-free survival in patients with pancreatic ductal adenocarcinoma.